CytRx (NASDAQ: CYTR) today presented interim results from its ongoing phase 1b/2 trail of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas, pushing shares higher in morning trade. At the European Society for Medical Oncology (ESMO) 2016 Congress being held in Copenhagen, Denmark, CytRx reported that: over 25% of sarcoma patients achieved a partial response for the target lesion while 61% had prolonged stable disease; six patients with unresectable tumors achieved greater than 50% tumor shrinkage, allowing some of them to become eligible for surgery; and there were no signs of cardiotoxicity, including in patients that received approximately 10 times the cumulative maximum dose of doxorubicin. “The results to date demonstrate that aldoxorubicin combined with ifosfamide provides significant clinical benefit for sarcoma patients,” Sant Chawla, M.D., F.R.A.C.P., the trial’s principal investigator and director of the Sarcoma Oncology Center in Santa Monica, California, stated in the news release.
To view the full press release, visit: http://nnw.fm/Jj7xm
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies. For more information visit www.cytrx.com
NetworkNewsBreak is a rapid summary of a press release that caught the attention of NetworkNewsWire (NNW). NNW provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit https://www.NetworkNewsWire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer